Chinese maker of peptide (polypeptide) active pharmaceutical ingredients and formulations.
Chinese maker of peptide (polypeptide) active pharmaceutical ingredients and formulations.
Moat: narrow (process know-how). Specialized peptide-synthesis manufacturing know-how versus small-molecule generic makers.
Headquarters: Shenzhen, China · Employees: 1,226
Size Hybio Pharmaceutical (300199.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.68B, the 883rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥21.49 on 18 Nov 2026.
Performance Over six months the shares fell 8.0%, against -11.8% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 70.2% over the last twelve months (peer median +2.6%); the operating margin is 31.4% (peer median 9.3%).
Valuation It trades at 44.7× forward earnings against a peer median of 24.2× (5th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +31 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.2 points above its cost of capital (14.0% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.53B | CN¥963M | CN¥590M | CN¥419M | CN¥688M |
| Revenue growth | — | +63% | +41% | -39% | — |
| Gross profit | CN¥1.03B | CN¥496M | CN¥264M | CN¥131M | CN¥467M |
| EBITDA | n/a | CN¥305M | CN¥110M | -CN¥223M | -CN¥42.2M |
| Net income | CN¥402M | CN¥36.6M | -CN¥174M | -CN¥514M | -CN¥371M |
| Free cash flow | CN¥17.1M | CN¥2.84M | CN¥54.1M | -CN¥85.3M | -CN¥173M |
| Capital expenditure | CN¥327M | CN¥234M | CN¥116M | CN¥81.8M | CN¥190M |
| Total debt | CN¥2.05B | CN¥1.92B | CN¥1.80B | CN¥2.00B | CN¥1.80B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hybio Pharmaceutical 300199.SZ | $2.68B | -8% | +70% | 31% | 44.7× | 37.4% |
| Bachem BANB.SW | $7.06B | 0% | +5% | 19% | 32.4× | n/a |
| PolyPeptide PPGN.SW | $1.61B | +7% | +22% | 7% | 52.1× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300199.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.9% | -3.6% | 4th lowest of 21 |
| 6-month return | -8.0% | -11.8% | 9th highest of 21 |
| Distance from 52-week high | -22.4% | -38.0% | 7th highest of 21 |
| Revenue growth (TTM) | +70.2% | +2.6% | 2nd highest of 21 |
| Operating margin | 31.4% | 9.3% | highest of 21 |
| Forward P/E | 44.7× | 24.2× | 5th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 37.4% | 11.7% | 4th most demanding of 15 |
| Growth delivered (Del g) | +6.1% | +10.5% | 6th lowest of 15 |
| Hurdle (Req g minus delivered) | +31.2 pp | -1.0 pp | most demanding of 15 |
| ROIC minus cost of capital | +1.2 pp | -0.9 pp | 7th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 44.7× | 37.4% | +6.1% |
| Betta Pharmaceuticals 300558.SZ | China | $2.70B | -15% | +16% | 11% | 38.0× | 23.2% | +14.0% |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 52.9× | 25.5% | +100.1% |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | n/a | n/a | n/a |
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | n/a | n/a | n/a |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.85B | 0% | -12% | 18% | 15.5× | -13.1% | +2.4% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.49B | -24% | -14% | 16% | 27.6× | 3.4% | +4.8% |
| Almirall ALM.MC | Spain | $2.46B | -13% | +24% | 8% | 27.1× | 6.1% | +6.5% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.95B | +28% | +50% | 26% | 63.4× | n/a | n/a |
| China Medical System 0867.HK | Hong Kong | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% | +2.7% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $2.99B | -1% | -11% | 24% | 20.1× | -3.3% | +7.0% |
| Vericel VCEL | United States | $2.99B | +66% | +25% | 8% | 68.3× | 46.5% | +17.3% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 10.6× | 2.3% | +2.9% |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 85.2× | 37.9% | +22.9% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 18.2× | n/a | n/a |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 35.9× | 47.0% | +19.3% |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | n/a | n/a | n/a |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | n/a | n/a | n/a |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% | +61.4% |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 6.7× | 14.1% | +0.8% |
| ACADIA Pharmaceuticals ACAD | United States | $3.08B | -15% | +15% | 10% | 17.8× | 9.2% | +19.4% |